Tianjin Lisheng Pharmaceutical Co Ltd Total Liabilities
Tianjin Lisheng Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Tianjin Lisheng Pharmaceutical Co Ltd (002393) has total liabilities worth CN¥893.57 Million CNY (≈ $130.76 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002393 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tianjin Lisheng Pharmaceutical Co Ltd (2006–2025)
Total liabilities of Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2025. This chart illustrates how Tianjin Lisheng Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Tianjin Lisheng Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Tianjin Lisheng Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Lisheng Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai W Ibeda High Tech Group Co Ltd
SHG:688071
|
China | CN¥1.23 Billion |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
China | CN¥1.37 Billion |
|
Voltalia SA
PA:VLTSA
|
France | €3.13 Billion |
|
Mercuries & Associates Holding Ltd
TW:2905
|
Taiwan | NT$1.52 Trillion |
|
Cubic Sensor and Instrument Co Ltd
SHG:688665
|
China | CN¥533.19 Million |
|
Nanjing CIGU Technology Corp. Ltd. A
SHG:688448
|
China | CN¥359.00 Million |
|
Zhejiang Langdi Group Co Ltd
SHG:603726
|
China | CN¥1.39 Billion |
|
Nilfisk Holding A/S
CO:NLFSK
|
Denmark | Dkr588.00 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Tianjin Lisheng Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tianjin Lisheng Pharmaceutical Co Ltd balance sheet assets.
Liquidity & Leverage Metrics
Tianjin Lisheng Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Tianjin Lisheng Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Lisheng Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Lisheng Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥890.89 Million ≈ $130.36 Million |
-9.60% |
| 2024-12-31 | CN¥985.54 Million ≈ $144.21 Million |
+12.35% |
| 2023-12-31 | CN¥877.17 Million ≈ $128.36 Million |
-6.85% |
| 2022-12-31 | CN¥941.66 Million ≈ $137.79 Million |
+20.66% |
| 2021-12-31 | CN¥780.42 Million ≈ $114.20 Million |
+8.38% |
| 2020-12-31 | CN¥720.09 Million ≈ $105.37 Million |
-15.86% |
| 2019-12-31 | CN¥855.85 Million ≈ $125.24 Million |
+21.42% |
| 2018-12-31 | CN¥704.85 Million ≈ $103.14 Million |
+17.02% |
| 2017-12-31 | CN¥602.32 Million ≈ $88.14 Million |
+27.99% |
| 2016-12-31 | CN¥470.60 Million ≈ $68.86 Million |
+7.07% |
| 2015-12-31 | CN¥439.50 Million ≈ $64.31 Million |
+30.07% |
| 2014-12-31 | CN¥337.89 Million ≈ $49.44 Million |
+13.31% |
| 2013-12-31 | CN¥298.20 Million ≈ $43.64 Million |
+101.31% |
| 2012-12-31 | CN¥148.13 Million ≈ $21.68 Million |
+131.22% |
| 2011-12-31 | CN¥64.07 Million ≈ $9.37 Million |
-16.93% |
| 2010-12-31 | CN¥77.12 Million ≈ $11.29 Million |
-81.25% |
| 2009-12-31 | CN¥411.26 Million ≈ $60.18 Million |
+51.99% |
| 2008-12-31 | CN¥270.58 Million ≈ $39.59 Million |
-38.77% |
| 2007-12-31 | CN¥441.87 Million ≈ $64.66 Million |
+6.47% |
| 2006-12-31 | CN¥415.03 Million ≈ $60.73 Million |
-- |
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more